Telomir Pharmaceuticals has announced new in vitro data demonstrating that its lead drug candidate, Telomir-1, inhibits three members of the KDM5 histone demethylase family. These enzymes are implicated in silencing tumor suppressor genes and activating inflammatory pathways, processes associated with cancer and aging. The company previously reported that Telomir-1 also targets KDM2 and KDM6 families and modulates DNA methylation. Importantly, Telomir-1 was shown to spare broad acetyltransferases such as GCN5L2, which are associated with systemic toxicity when inhibited.
By acting at both the histone and DNA levels, Telomir-1 is emerging as a first-in-class, broad-spectrum epigenetic reset therapy with the potential to restore fundamental cellular defenses relevant to cancer and aging. The company continues to advance IND-enabling studies and GMP scale-up for Telomir-1, with additional preclinical evaluations ongoing across aggressive cancers and models of aging. The company expects these findings to support its upcoming IND submission.
Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing therapies that target the root causes of cancer, aging, and age-related diseases.
